Alteration of regional cerebral blood flow to thyrotropin-releasing hormone therapy in acute encephalitis and encephalopathy during childhood

Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT

“…Therefore, a more objective and quantitative method is necessary to elucidate the efficacy of TRH therapy. Although manual quantitative measurements of rCBF have been used to assess the effects of TRH, the reproducibility and objectivity of the results are problematic [3,9]. In the present study, the rCBF in each ROI was measured automatically and objectively using a fully automated ROI technique, 3DSRT.…”

“…TRH also has neuroprotective effects as a neuromodulator or neurotransmitter in the brain [1], and is therefore often used as a therapeutic agent in cases of encephalitis, trauma [2,3], brain ischemia [4], and neurodegenerative disorders [5,6]. TRH administered intravenously at a dose of 2 mg/day for 14 days significantly improves cerebellar ataxia in patients with spinocerebellar degeneration (SCD) [7,8].…”

“…Evaluation of the efficacy of TRH therapy based on clinical parameters is difficult because the degree of clinical improvement is slight and depends on the disease severity. Although brain perfusion single photon emission computed tomography (SPECT) has been used to evaluate cerebral function and to measure regional cerebral blood flow (rCBF) quantitatively using manual settings to determine the region of interest (ROI), both the reproducibility and objectivity of the results are problematic because the ROIs on the SPECT referential slice must be set equally for every patient [3,9]. Brain perfusion analyzing programs, such as eZIS and 3DSRT, were recently developed to address these problems.…”

Evaluation of the Effects of Thyrotropin Releasing Hormone (TRH) Therapy on Regional Cerebral Blood Flow in the Cerebellar Variant of Multiple System Atrophy Using 3DSRT

“…We performed the quantitative analyses of the rCBF in each ROI before and after TRH intravenous administration at a dose of 2 mg/day for 14 days to evaluate the efficacy of TRH treatment in patients with MSA‐C. Although manual quantitative measurements of rCBF have been used to assess the effects of TRH, the reproducibility and objectivity of the results are problematic 3,24 . We measured automatically and objectively the rCBF in each ROI using a fully automated ROI technique, 3DSRT.…”

“…Thyrotropin releasing hormone (TRH) regulates the release of thyrotropin from the pituitary gland. TRH also has neuroprotective effects as a neuromodulator or neurotransmitter in the brain, 1 and is therefore used as a therapeutic agent in cases of encephalitis, trauma, 2,3 brain ischemia, 4 and neurodegenerative disorders 5,6 . TRH administered intravenously at a dose of 2 mg/day for 14 days significantly improves cerebellar ataxia in patients with spinocerebellar degeneration (SCD) 7,8 .…”